ImmuPharma is one of the leading specialist drug development companies listed on AIM of the LSE
Developing innovative drugs
ImmuPharma PLC is one of the leading specialist drug development companies listed on AIM of the LSE. Our corporate strategy and business model differentiates us from many of our peers.
We have UK, French and Swiss operations and have a formal research collaboration with Europe’s largest fundamental research organization in Europe, the Centre National de la Recherche Scientifique (CNRS). ImmuPharma has received to-date $45 million from a corporate deal with a US pharmaceutical company and a number of grants from French government organisations for three of our drug candidates. Our most advanced compound has recently been given the approval from the US FDA to enter phase III with a special protocol assessment and Fast Track designation.
With a partnership-based business model, a small core of full time staff, a low R&D costbase, a strong balance sheet and diversified compounds and pipeline, we believe we are a risk adverse and exciting pharma/biotech opportunity.
ImmuPharma PLC has an impressive list of shareholders/investors, both institutional as well as private clients that have supported the Company through its history and have helped finance product development.
Nexia Smith & Williamson Audit Limited,
Bircham Dyson Bell LLP
Badertscher Rechtsanwälte AG, Zurich, Switzerland
McCarter & English, LLP, Connecticut, USA
Cabinet Regimbeau, Paris, France
Grosset-Fournier & Demachy, Paris, France
Under contract with a leading manufacturer in the peptides field